Celestis Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
- Paid Up Capital ₹ 1.38 M
- Company Age 10 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -72.57%
- Profit Growth 31.67%
- Ebitda 79.09%
- Net Worth -40.19%
- Total Assets -12.96%
About Celestis Pharmaceuticals
Celestis Pharmaceuticals Private Limited (CPPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 June 2014 and has a history of Ten years and seven months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.38 M, as per Ministry of Corporate Affairs (MCA) records.
Mousumi Mandal, Pravin Thombare, and Sunita Thombare serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24100GJ2014PTC079868
-
Company No.
079868
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Jun 2014
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Celestis Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mousumi Mandal
|
Director | 23-Jun-2014 | Current |
|
Pravin Thombare
|
Director | 23-Jun-2014 | Current |
|
Sunita Thombare
|
Director | 23-Jun-2014 | Current |
Financial Performance of Celestis Pharmaceuticals.
Celestis Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 72.57% decrease. The company also saw a substantial improvement in profitability, with a 31.67% increase in profit. The company's net worth observed a substantial decline by a decrease of 40.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Celestis Pharmaceuticals?
In 2019, Celestis Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Jsm Innovations LlpMousumi Mandal is a mutual person
-
Apdm Pharmaceuticals Private Limited
Mousumi Mandal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Celestis Pharmaceuticals?
Unlock and access historical data on people associated with Celestis Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Celestis Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Celestis Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
